Browsing by Author Hu, Jianda

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Showing results 1 to 20 of 32 next >
Issue Date Title Author(s)
2019 Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study Wang, Ling;Wang, Ying;Hu, Jiong;Sun, Yuqian;Huang, He;Chen, Jing;Li, Jianyong;Ma, Jun;Li, Juan;Liang, Yingmin;Wang, Jianmin;Li, Yan;Yu, Kang;Hu, Jianda;Jin, Jie;Wang, Chun;Wu, Depei;Xiao, Yang;Huang, Xiaojun
Apr-2021 Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study Sun, Yuqian;Hu, Jiong;Huang, He;Chen, Jing;Li, Jianyong;Ma, Jun;Li, Juan;Liang, Yingmin;Wang, Jianmin;Li, Yan;Yu, Kang;Hu, Jianda;Jin, Jie;Wang, Chun;Wu, Depei;Xiao, Yang;Huang, Xiaojun
Aug-2022 Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthere (R)) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial Shi, Yuankai;Zhang, Qingyuan;Hong, Xiaonan;Wang, Zhen;Gao, Yuhuan;Zou, Liqun;Cen, Hong;Gui, Lin;Li, Yufu;Feng, Jifeng;Wang, Zhao;Zhang, Mingzhi;Jin, Chuan;Zhang, Weihua;Hu, Jianda;Zheng, Chengyun;Zheng, Zhendong;Zhang, Liling;Chen, Shaoshui;Huang, Yunhong;Tang, Yun;Gao, Yajie;Hao, Miaowang;Li, Xiaoling;Chang, Chunkang;Yang, Haiyan;Wu, Hui;Shen, Lida;Ke, Xiaoyan;Zhang, Liangming;Xi, Yaming;Yang, Linhua;Xie, Liangzhi;Gai, Wenlin;Ji, Yanan
Sep-2021 Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study Lu, Jin;Fu, Weijun;Li, Wei;Hu, Jianda;An, Gang;Wang, Yafei;Fu, Chengcheng;Chen, Lijuan;Jin, Jie;Cen, Xinan;Ge, Zheng;Cai, Zhen;Niu, Ting;Qi, Ming;Sun, Steven;Gai, Xue;Liu, Weiping;Liu, Wenyu;Yang, Xue;Huang, Xiaojun
Jan-2023 Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory of LEPUS Fu, Weijun;Li, Wei;Hu, Jianda;An, Gang;Wang, Yafei;Fu, Chengcheng;Chen, Lijuan;Jin, Jie;Cen, Xinan;Ge, Zheng;Cai, Zhen;Niu, Ting;Qi, Ming;Gai, Xue;Li, Qian;Liu, Weiping;Liu, Wenyu;Yang, Xue;Chen, Xi;Lu, Jin
2016 Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy A Multicenter, Prospective, Observational Study in China Wang, Ling;Hu, Jiong;Sun, Yuqian;Huang, He;Chen, Jing;Li, Jianyong;Ma, Jun;Li, Juan;Liang, Yingmin;Wang, Jianmin;Li, Yan;Yu, Kang;Hu, Jianda;Jin, Jie;Wang, Chun;Wu, Depei;Xiao, Yang;Huang, Xiaojun
2018 Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance Zhang, Jingru;Wang, Yingqiao;Wang, Jianxiang;Hu, Jianda;Chen, Suning;Jin, Jie;Liu, Ting;Zhou, Jianfeng;Hu, Yu;Ma, Daoxin;Huang, Xiaojun;Ji, Chunyan;Hou, Ming
2018 Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study Zheng, Xiaoyun;Huang, Xiaobo;Luo, Jianmin;Li, Juan;Li, Wei;Liu, Qifa;Niu, Ting;Wang, Xiaodong;Zhou, Jianfeng;Zhang, Xi;Hu, Jianda;Liu, Kaiyan
Nov-2020 Fluconazole is as effective as other anti-mold agents in preventing early invasive fungal disease after allogeneic stem cell transplantation: assessment of antifungal therapy in haematological disease in China Sun, Yuqian;Hu, Jiong;Huang, He;Chen, Jing;Li, Jianyong;Ma, Jun;Li, Juan;Liang, Yingmin;Wang, Jianmin;Li, Yan;Yu, Kang;Hu, Jianda;Jin, Jie;Wang, Chun;Wu, Depei;Xiao, Yang;Huang, Xiaojun
2019 Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety Huang, Xiaojun;Jiang, Qian;Hu, Jianda;Li, Jianyong;Jin, Jie;Meng, Fanyi;Shen, Zhixiang;Liu, Ting;Wu, Depei;Wang, Jianmin;Wang, Jianxiang
2012 Homoharringtonine-Based Induction Regimens for Patients with De Novo Acute Myeloid Leukemia: A Multicenter Randomized Controlled Phase 3 Trial Jin, Jie;Wang, Jianxiang;Chen, Feifei;Wu, Depei;Hu, Jiong;Zhou, Jianfeng;Hu, Jianda;Wang, Jianmin;Li, Jianyong;Huang, Maojun;Ma, Jun;Ji, Chunyan;Xu, Maoping;Yu, Kang;Ren, Hanyun;Zhou, Yuhong;Tong, Yin;Mi, Yingchang;Du, Xin;Chen, Baoan;Chen, Zhu;Chen, Sai-Juan
2015 Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China Sun, Yuqian;Huang, He;Chen, Jing;Li, Jianyong;Ma, Jun;Li, Juan;Liang, Yingmin;Wang, Jianmin;Li, Yan;Yu, Kang;Hu, Jianda;Jin, Jie;Wang, Chun;Wu, Depei;Xiao, Yang;Huang, Xiaojun
15-Nov-2022 Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study Yang, Sen;Zhang, Xiaoshuai;Zhang, Yanli;Du, Xin;Weng, Jianyu;Zhu, Huanling;Pan, Ling;Yang, Yun-fan;Meng, Li;Liu, Zhenfang;Liu, Xiaoli;Xu, Na;Chen, Chunyan;Wang, Xiaodong;Liang, Rong;Huang, Jian;Li, Guohui;Liu, Chunshui;Lin, Hai;Hu, Jianda;Fei, Li;Liu, Bingcheng;Li, Weiming;Liu, Zhuogang;Yang, Wei;Huang, Xiao Jun;Jiang, Qian
15-Nov-2022 Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis Song, Yuqin;Zhou, Keshu;Zou, Dehui;Li, Dengju;Hu, Jianda;Yang, Haiyan;Zhang, Huilai;Ji, Jie;Xu, Wei;Jin, Jie;Lv, Fangfang;Feng, Ru;Gao, Sujun;Zhou, Daobin;Tam, Constantine S.;Simpson, David;Wang, Michael L.;Phillips, Tycel J.;Opat, Stephen;Fang, Cheng;Sun, Shaohui;Zhu, Jun
4-Nov-2021 A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China Liu, Weiping;Zhao, Donglu;Liu, Ting;Niu, Ting;Song, Yongping;Xu, Wei;Jin, Jie;Cai, Qingqing;Huang, Huiqiang;Li, Zhiming;Hou, Ming;Zhang, Huilai;Zhou, Jianfeng;Hu, Jianda;Shen, Jianzhen;Shi, Yuankai;Yang, Yu;Zhang, Liling;Zhao, Weili;Ding, Kaiyang;Qiu, Lugui;Tan, Huo;Zhang, Zhihui;Liu, Lihong;Wang, Jinghua;Xu, Bing;Zhou, Hui;Gao, Guangxun;Xue, Hongwei;Bai, Ou;Feng, Ru;Huang, Xiaobing;Yang, Haiyan;Yan, Xiaojing;Zeng, Qingshu;Liu, Peng;Li, Wenyu;Mao, Min;Su, Hang;Wang, Xin;Xu, Jingyan;Zhou, Daobin;Zhang, Hongyu;Ma, Jun;Shen, Zhixiang;Zhu, Jun
2011 A Multicenter, Open-Label Study of Posaconazole Oral Suspension in Treatment of Patients with Invasive Fungal Infection Refractory to or Intolerant of First-Line Therapy Huang, Xiaojun;Wang, Fengrong;Chen, Yuhong;Liu, Ting;Wang, Jianxiang;Hu, Jianda;Jin, Jie;Chen, Fangping;Wang, Shujie;Shen, Zhixiang;Yu, Li;Yu, Kang;Liang, Yingmin
2012 A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy Huang, Xiaojun;Wang, Fengrong;Chen, Yuhong;Liu, Ting;Wang, Jianxiang;Hu, Jianda;Jie, Jin;Chen, Fangping;Wang, Shujie;Shen, Zhixiang;Yu, Li;Yu, Kang;Liang, Yingmin
25-Feb-2021 A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia Mei, Heng;Liu, Xiaofan;Li, Yan;Zhou, Hu;Feng, Ying;Gao, Guangxun;Cheng, Peng;Huang, Ruibin;Yang, Linhua;Hu, Jianda;Hou, Ming;Yao, Yazhou;Liu, Li;Wang, Yi;Wu, Depei;Zhang, Liansheng;Zheng, Changcheng;Shen, Xuliang;Hu, Qi;Liu, Jing;Jin, Jie;Luo, Jianmin;Zeng, Yun;Gao, Sujun;Zhang, Xiaohui;Zhou, Xin;Shi, Qingzhi;Xia, Ruixiang;Xie, Xiaobao;Jiang, Zhongxing;Gao, Li;Bai, Yuansong;Li, Yan;Xiong, Junye;Li, Runzi;Zou, Jianjun;Niu, Ting;Yang, Renchi;Hu, Yu
Jan-2023 Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study Xu, Wei;Zhou, Keshu;Wang, Tingyu;Yang, Shenmiao;Liu, Lihong;Hu, Yu;Zhang, Wei;Ding, Kaiyang;Zhou, Jianfeng;Gao, Sujun;Xu, Bing;Zhu, Zunmin;Liu, Ting;Zhang, Huilai;Hu, Jianda;Ji, Chunyan;Wang, Shunqing;Xia, Zhongjun;Wang, Xin;Li, Yan;Song, Yongping;Ma, Shuo;Tang, Xinran;Zhang, Bin;Li, Jianyong
2013 Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM) Wang, Jianxiang;Huang, Xiaojun;Hu, Jianda;Li, Jianyong;Jin, Jie;Meng, Fanyi;Shen, Zhixiang;Liu, Ting;Wu, Depei;Wang, Jianmin
Showing results 1 to 20 of 32 next >